Despite Uneven Results, Alzheimer's Research Suggests A Path For Treatment : Shots - Health News The year saw some disappointments in the development of drugs to treat Alzheimer's. But the setbacks were offset by progress in other areas. The upshot from this year's mixed results, some scientists say, is that treatment for Alzheimer's needs to start long before forgetfulness and muddled thinking are apparent.
NPR logo

Despite Uneven Results, Alzheimer's Research Suggests A Path For Treatment

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Despite Uneven Results, Alzheimer's Research Suggests A Path For Treatment

Despite Uneven Results, Alzheimer's Research Suggests A Path For Treatment

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


For researchers studying Alzheimer's, 2012 has been a year of ups and downs. The bad news was that some promising drugs failed to stop or even slow the disease. But researchers also found new reasons to believe treatments can work if they just begin sooner. NPR's Jon Hamilton tells us more.

JON HAMILTON, BYLINE: Scientists who study Alzheimer's say they aren't discouraged by the drug failures.

DR. WILLIAM REBECK: I actually think it was a phenomenal year for research.

HAMILTON: Bill Rebeck is a brain scientist at Georgetown University. He says he's optimistic because during the year, several very different lines of research all began to suggest a new way of thinking about Alzheimer's - that it has to be stopped before it damages the brain.

REBECK: Once you start to lose a lot of synapses, once you start to lose a lot of neurons, your brain can't recover from that. And so when we start with people who have symptoms of the disease, treating them turns out to be unsuccessful.

HAMILTON: Rebeck says that explanation comes in part from results of studies that used a new research tool approved by the FDA in April. The tool is a substance that's injected into the bloodstream and travels to amyloid plaques in the brain, the same plaques that are associated with Alzheimer's. Rebeck says this lets researchers detect even tiny plaques using a PET scanner.

REBECK: In the PET scan, you can see whether somebody has amyloid in their brain or they don't have amyloid in their brain before somebody shows symptoms of the disease. I think that's huge.

HAMILTON: Rebeck says researchers have already used the technique to show that amyloid begins to build up decades before people start having problems with memory or thinking. And he says it should also provide a much quicker way to gauge whether a new Alzheimer's treatment is working.

Another advance this year was a study showing that the brain begins to function differently long before symptoms of Alzheimer's appear. Lori Beason-Held of the National Institute on Aging presented the study at the Society for Neuroscience meeting. She says previous research had found brain changes among people in the early stages of Alzheimer's.

DR. LORI BEASON-HELD: Our study has gone back even further and discovered changes in the brain that occur up to 11 years before any symptoms occur in individuals who eventually become cognitively impaired.

HAMILTON: Beason-Held says the changes probably start even earlier. Bill Rebeck says that might sound discouraging, but he doesn't see it that way.

REBECK: What that says is there's an opportunity, there's a window when if we could stop that amyloid from accumulating or start to clear it out of the brain, then you could prevent those symptoms from actually ever happening.

HAMILTON: And another study this year suggests a way to do that. Researchers in Iceland discovered that families with a rare gene mutation are much less likely to get Alzheimer's. The mutation appears to interrupt a key step in the formation of amyloid. Robert Vassar of Northwestern University says in order to form amyloid, the brain first has to cut up a larger molecule. He says this requires an enzyme called beta-secretase, or BACE 1.

DR. ROBERT VASSAR: BACE 1 is like a pair of molecular scissors, and what the mutation does is sort of interfere with the way the molecular scissors can cut. It sort of, like, dulls the blades.

HAMILTON: Bill Rebeck says just a few months ago, researchers came up with a drug that does the same thing family members with the gene mutation do naturally.

REBECK: This genetic family says, you know, there's a real reason to believe that that will be helpful.

HAMILTON: Though this drug also may have to be started before amyloid has begun to build up. Michael Rafii of UC San Diego says the new thinking about amyloid and Alzheimer's is a bit like the current approach to cholesterol and heart disease. Rafii says doctors don't wait until someone has a heart attack before putting them on a drug that lowers cholesterol.

DR. MICHAEL RAFII: Really the ideal situation is to have checked their cholesterol levels 15 years prior and seen whether it was elevated, which would imply that they have an elevated risk of having the heart attack, and starting the medication then.

HAMILTON: But Bill Rebeck says it's not clear whether amyloid is the new cholesterol.

REBECK: It took a long time for us to make that connection between cholesterol and heart disease. That's been very successful. It's been very helpful in so many people's lives. We're just earlier stages in studying Alzheimer's disease.

HAMILTON: In 2013, researchers will launch several large studies that try to prevent the sort of brain damage that leads to Alzheimer's. Jon Hamilton, NPR News.

Copyright © 2012 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.